article thumbnail

Oral COVID Agents

Pharmacy Friday Pearls

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

article thumbnail

Nine for 2022: International issues that are compelling, new or changed in 2022

pharmaphorum

Add to this the fact that the world missed the WHO targets for global vaccination by the end of 2021 and will likely continue to miss targets in 2022. The next phase of the Covid-19 – from vaccines to treatments. New COVID-19 treatments will also be available in 2022, but they are not a panacea.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ivermectin: A therapeutic approach to reduce high-risk cases of COVID

Druggist

In January 2021, the pilot study was led using 27 random controlled trials, out of which 15 attendants confirmed Ivermectin to be effective. Additionally, this drug is also known as anti-parasite successful against all viruses like HIV, Dengue, Influenza , and Zika virus. And stated its judicial use in preventing corona infection.

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. The scope of the problem.

article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

billion US in 2021 to $1.9 1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. In 2021, CONTINUUS Pharmaceuticals secured a$69.3 This is demonstrated by the rise from $1.05

article thumbnail

How Balancing Iron Levels Can Help Your Thyroid

The Thyroid Pharmacist

And as we’ve seen, even with supplementation, you need to address your root causes to prevent iron supply and demand challenges. Viruses that have been associated with anemia include Epstein-Barr Virus , hepatitis A and C, human herpes virus 6 (HHV-6), cytomegalovirus, parvovirus B19, and HIV. [45] However, when they added 1.5